"description","label","uuid:ID","name","text","instanceType","id"
"Main objective","","0324ad86-6be2-49f3-b866-00806e734c35","OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective","Objective_1"
"Safety","","9d96bbd7-d242-4695-be42-23dc8b9158d8","OBJ2","To document the safety profile of the xanomeline TTS.","Objective","Objective_2"
"Behaviour","","d2ae79bb-c245-49f6-b90f-fa8f5c5e5cc9","OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective","Objective_3"
"","","ff893483-df62-4325-afda-941c8b024740","OBJ4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective","Objective_4"
"","","e8f36f87-9c8a-45ca-bb59-64221533c581","OBJ5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective","Objective_5"
"","","45ef839c-191a-40b3-8eff-d29e5965f5ab","OBJ6","To assess the treatment response as a function of Apo E genotype.","Objective","Objective_6"
